Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6391
Peer-review started: October 7, 2014
First decision: October 29, 2014
Revised: December 6, 2014
Accepted: February 5, 2015
Article in press: February 5, 2015
Published online: May 28, 2015
We present a case of a patient with hypersplenism secondary to portal hypertension due to hepato-splenic schistosomiasis, which was accompanied by severe and refractory thrombocytopenia. We performed spleen ablation and measured the total spleen and ablated volumes with contrast-enhanced computed tomography and volumetry. No major complications occurred, thrombocytopenia was resolved, and platelet levels remained stable, which allowed for early treatment of the patient’s underlying disease. Previous work has shown that splenic radiofrequency ablation is an attractive alternative treatment for hypersplenism induced by liver cirrhosis. We aimed to contribute to the currently sparse literature evaluating the role of radiofrequency ablation (RFA) in the management of hypersplenism. We conclude that splenic RFA appears to be a viable and promising option for the treatment of hypersplenism.
Core tip: The role of splenic radiofrequency ablation (RFA) in the management of hypersplenism is still under study, and the current literature is sparse. This case report not only presents splenic RFA as an attractive alternative treatment for hypersplenism induced by liver cirrhosis, but also shows that it appears to be a viable, safe and promising option for these patients.